Preexposure Prophylaxis and Prevention
LTC Jason Blaylock, MD. Although emtricitabine/tenofovir disoproxil fumarate (Truvada, Gilead Sciences, Foster City, CA) for use as HIV preexposure prophylaxis (PrEP) was approved by the US Food and Drug Administration (FDA) in 2012, the military health care system (MHS) really didn’t start to use it until early 2014. Here at Walter Reed National Military Medical Center (WRNMMC), we started a PrEP clinic within the Infectious Disease clinic. This eventually served as a model for other military treatment facilities (MTFs), and our providers continue to advise others regarding initiating PrEP clinics throughout the MHS.